The estimated Net Worth of Michael A Jr Mcmanus is at least $4.1 Million dollars as of 14 August 2024. Mr. Mcmanus owns over 135,000 units of Novavax stock worth over $2,683,313 and over the last 21 years he sold NVAX stock worth over $1,280,590. In addition, he makes $134,296 as Independent Director at Novavax.
Michael has made over 38 trades of the Novavax stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 135,000 units of NVAX stock worth $51,300 on 14 August 2024.
The largest trade he's ever made was buying 135,000 units of Novavax stock on 14 August 2024 worth over $51,300. On average, Michael trades about 7,633 units every 76 days since 2003. As of 14 August 2024 he still owns at least 218,333 units of Novavax stock.
You can see the complete history of Mr. Mcmanus stock trades at the bottom of the page.
Michael A. McManus Jr. J.D. serves as Independent Director of the Company. Mr. McManus is Former President and Chief Executive Officer of Misonix, Inc. from 1999 to 2016. Mr. McManus served as President, Chief Executive Officer and Director of New York Bancorp Inc. from 1991 through March 1998. He also served as President and Chief Executive Officer of Home Federal Savings Bank, the principal subsidiary of New York Bancorp Inc., from February 1995 through March 1998. From 1990 through November 1991, Mr. McManus was President and Chief Executive Officer of Jamcor Pharmaceuticals Inc. Mr. McManus served as an Assistant to the President of the United States from 1982 to 1985 and held positions with Pfizer Inc. and Revlon Group. Mr. McManus served in the U.S. Army Infantry from 1968 through 1970. Mr. McManus is a recipient of the Ellis Island Medal of Honor. Mr. McManus received a B.A. in economics from the University of Notre Dame and a J.D. from the Georgetown University Law Center.
As the Independent Director of Novavax, the total compensation of Michael McManus at Novavax is $134,296. There are 9 executives at Novavax getting paid more, with Stanley Erck having the highest compensation of $2,438,560.
Michael McManus is 77, he's been the Independent Director of Novavax since 1998. There are no older and 22 younger executives at Novavax.
Michael's mailing address filed with the SEC is 47 COX GULCH ROAD, , THOMPSON FALLS, MT, 59873.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: